A role for antiangiogenic therapy in breast cancer

Current Oncology Reports

Volumn 6, Issue 1, 2004, Pages 42-48

  Moses, Marsha A ^a   Harper, Jay ^a   Fernández, Cecilia A ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CELECOXIB; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; FLUOROURACIL; INSULIN; INTERLEUKIN 12; INTERLEUKIN 2; ISOFLAVONE; METHOTREXATE; PACLITAXEL; TAMOXIFEN; THALIDOMIDE; TRASTUZUMAB; VASCULOTROPIN INHIBITOR;

BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLON CANCER; DIABETES MELLITUS; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG TOLERABILITY; EARLY MENOPAUSE; ENDOMETRIUM HYPERPLASIA; FEMALE; HAIR LOSS; HEART FAILURE; HUMAN; LUNG EMBOLISM; METASTASIS; NAUSEA; OSTEOPENIA; OVARY CYST; REVIEW; THROMBOEMBOLISM; TUMOR VASCULARIZATION;

EID: 3142630381     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-996-0008-6     Document Type: Review

References (61)

1. Folkman J: Angiogenesis and breast cancer. J Clin Oncol 1994, 12:441-443.
2. Folkman J: The influence of angiogenesis research on management of patients with breast cancer. Breast Cancer Res Treat 1995, 36:109-118.
3. Folkman J: Angiogenesis in breast cancer. In The Breast. Edited by Bland KC. Philadelphia: WB Saunders; 1998:586-603.
4. Rayson D, Vantyghem SA, Chambers AF: Angiogenesis as a target for breast cancer therapy. J Mammary Gland Biol Neoplasia 1999, 4:415-423.
5. Wu I, Moses MA: Angiogenic molecules and mechanisms in breast cancer. Curr Oncol Rep 2000, 2:566-571.
6. Fisher B, Dignam J, Wolmark N, et al.: Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 1998, 16:441-452.
7. Julien JP, Bijker N, Fentiman IS, et al.: Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomized phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet 2000, 355:528-533.
8. Lingos TI, Recht A, Vicini F, et al.: Radiation pneumonitis in breast cancer patients treated with conservative surgery and radiation therapy. Int J Radiat Oncol Biol Phys 1991, 21:355-360.
9. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomized trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 2000, 355:1757-1770.
10. Fisher B, Anderson S, Tan-Chiu E, et al.: Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 2001, 19:931-942.
11. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998, 351:1451-1467.
12. Fisher B, Dignam J, Wolmark N, et al.: Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 1997, 89:1673-1682.
13. Fisher B, Redmond C, Legault-Poisson S, et al.: Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 1990, 8:1005-1018.
14. Saphner T, Tormey DC, Gray R: Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991, 9:286-294.
15. Fornander T, Rutqvist LE, Cedermark B, et al.: Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989, 1:117-120.
16. Shushan A, Peretz T, Uziely B, et al.: Ovarian cysts in premenopausal and postmenopausal tamoxifen-treated women with breast cancer. Am J Obstet Gynecol 1996, 174:141-144.
17. Powles TJ, Hickish T, Kanis JA, et al.: Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996, 14:78-84.
18. Pritchard KI, Paterson AH, Paul NA, et al.: Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol 1996, 14:2731-2737.
19. Shapiro CL, Manola J, Leboff M: Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 2001, 19:3306-3311.
20. Peters W, Rosner G, Vrendenburgh J, et al.: A prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13. Proc ASCO 1999, 18:A-2.
21. Cobleigh MA, Vogel CL, Tripathy D, et al.: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999, 17:2639-2648.
22. Slamon DJ, Leyland-Jones B, Shak S, et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
23. Seidman A, Hudis C, Pierri MK, et al.: Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002, 20:1215-1221.
24. Fang J, Shing Y, Wiederschain D, et al.: Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci U S A 2000, 97:3884-3889.
25. Bergers G, Brekken R, McMahon G, et al.: Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000, 2:737-44.
26. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364.
27. Yoshiji H, Harris SR, Thorgeirsson UP: Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells. Cancer Res 1997, 57:3924-3928.
28. Fang J, Yan L, Shing Y, et al.: HIF-1alpha-mediated up-regulation of vascular endothelial growth factor, independent of basic fibroblast growth factor, is important in the switch to the angiogenic phenotype during early tumorigenesis. Cancer Res 2001, 61:5731-5735.
29. Green JE, Shibata MA, Yoshidome K, et al.: The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma. Oncogene 2000, 19:1020-1027.
30. Li M, Lewis B, Capuco AV, et al.: WAP-TAg transgenic mice and the study of dysregulated cell survival, proliferation, and mutation during breast carcinogenesis. Oncogene 2000, 19:1010-1019.
31. Yokoyama Y, Green JE, Sukhatme VP, et al.: Effect of endostatin on spontaneous tumorigenesis of mammary adenocarcinoma in a transgenic mouse model. Cancer Res 2000, 60:4362-4365.
32. Calvo A, Yokoyama Y, Smith LE, et al.: Inhibition of the mammary carcinoma angiogenic switch in C3(1)/SV40 transgenic mice by a mutated form of human endostatin. Int J Cancer 2002, 101:224-234.
33. O'Reilly MS, Boehm T, Shing Y, et al.: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88:277-285.
34. Perletti G, Concari P, Giardini R, et al.: Antitumor activity of endostatin against carcinogen-induced rat primary mammary tumors. Cancer Res 2000, 60:1793-1796.
35. Relf M, LeJeune S, Scott PA, et al.: Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997, 57:963-969.
36. Moses MA, Wiederschain D, Loughlin KR, et al.: Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res 1998, 58:1395-1399.
37. O'Reilly MS, Wiederschain D, Stetler-Stevenson WG, et al.: Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J Biol Chem 1999, 274:29568-29571.
38. Camphausen K, Moses MA, Beecken WD, et al.: Radiation therapy to a primary tumor accelerates metastatic growth in mice. Cancer Res 2001, 61:2207-2211.
39. Moses MA, Sudhalter J, Langer R: Identification of an inhibitor of neovascularization from cartilage. Science 1990, 248:1408-1410.
40. Johnson MD, Kim HR, Chesler L, et al.: Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. J Cell Physiol 1994, 160:194-202.
41. Anand-Apte B, Pepper MS, Voest E, et al.: Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3. Invest Ophthalmol Vis Sci 1997, 38(5):817-823.
42. Montesano R, Orci L: Tumor-promoting phorbol esters induce angiogenesis in vitro. Cell 1985, 42(2):469-477.
43. Mignatti P, Tsuboi R, Robbins E, et al.: In vitro angiogenesis on the human amniotic membrane: requirement for basic fibroblast growth factor-induced proteinases. J Cell Biol 1989, 108:671-682.
44. Murphy AN, Unsworth EJ, Stetler-Stevenson WG: Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J Cell Physiol 1993, 157:351-358.
45. Herron GS, Banda MJ, Clark EJ, et al.: Secretion of metalloproteinases by stimulated capillary endothelial cells. II. Expression of collagenase and stromelysin activities is regulated by endogenous inhibitors. J Biol Chem 1986, 261:2814-2818.
46. Moscatelli D, Jaffe E, Rifkin DB: Tetradecanoyl phorbol acetate stimulates latent collagenase production by cultured human endothelial cells. Cell 1980, 20:343-351.
47. Gross JL, Moscatelli D, Jaffe EA, et al.: Plasminogen activator and collagenase production by cultured capillary endothelial cells. J Cell Biol 1982, 95:974-981.
48. Unemori EN, Bouhana KS, Werb Z: Vectorial secretion of extracellular matrix proteins, matrix-degrading proteinases, and tissue inhibitor of metalloproteinases by endothelial cells. J Biol Chem 1990, 265:445-451.
49. Hanemaaijer R, Koolwijk P, le Clercq L, et al.: Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells: effects of tumour necrosis factor alpha, interleukin 1 and phorbol ester. Biochem J 1993, 296:803-809.
50. Fisher C, Gilbertson-Beadling S, Powers EA, et al.: Interstitial collagenase is required for angiogenesis in vitro. Dev Biol 1994, 162:499-510.
51. Unemori EN, Ferrara N, Bauer EA, et al.: Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol 1992, 153:557-562.
52. Lamoreaux WJ, Fitzgerald ME, Reiner A, et al.: Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. Microvasc Res 1998, 55:29-42.
53. Zucker S, Mirza H, Conner CE, et al.: Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation. Int J Cancer 1998, 75:780-786.
54. Yan L, Borregaard N, Kjeldsen L, et al.: The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL): modulation of MMP-9 activity by NGAL. J Biol Chem 2001, 276:37258-37265.
55. Nguyen M, Watanabe H, Budson AE, et al.: Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients. J Natl Cancer Inst 1993, 85:241-242.
56. Nguyen M, Watanabe H, Budson AE, et al.: Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 1994, 86:356-361.
57. Ezekowitz A, Mulliken J, Folkman J: Interferon alpha therapy of haemangiomas in newborns and infants. Br J Haematol 1991, 79(Suppl 1):67-68.
58. Chang E, Boyd A, Nelson CC, et al.: Successful treatment of infantile hemangiomas with interferon-alpha-2b. J Pediatr Hematol Oncol 1997, 19:237-244.
59. Weidner N, Semple JP, Welch WR, et al.: Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991, 324:1-8.
60. Hahnfeldt P, Folkman J, Hlatky L: Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis. J Theor Biol 2003, 220:545-554.
61. McCarthy M: Antiangiogenesis drug promising for metastatic colorectal cancer. Lancet 2003, 361:1959.